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Background: Host cellular tRNALys3 is exclusively utilized by human immunodeficiency virus type 1 (HIV-1) as a
primer for the replication step of reverse transcription (RTion). Consequently, the priming step of HIV-1 RT
constitutes a potential target for anti-HIV-1 intervention. Previous studies indicated that a mutant tRNALys3 with 7-
nucleotide substitutions in the 3′ terminus resulted in aberrant HIV-1 RTion from the trans-activation response
region (TAR) and inhibition of HIV-1 replication. However, the mutant tRNALys3 also directed HIV-1 RTion from the
normal primer-binding site (PBS) with potentially weakened anti-HIV-1 activity. To achieve improved targeting of
HIV-1 RTion at sites not including the PBS, a series of mutant tRNALys3 with extended lengths of mutations
containing up to 18 bases complementary to their targeting sites were constructed and characterized.
Results: A positive correlation between the length of mutation in the 3′ PBS-binding region of tRNALys3 and the
specificity of HIV-1 RTion initiation from the targeting site was demonstrated, as indicated by the potency of HIV-1
inhibition and results of priming assays. Moreover, two mutant tRNALys3s that targeted the IN-encoding region and
Env gene, respectively, both showed a high anti-HIV-1 activity, suggesting that not only the TAR, but also distant
sites downstream of the PBS could be effectively targeted by mutant tRNALys3. To increase the expression of
mutant tRNALys3, multiple-copy expression cassettes were introduced into target cells with increased anti-HIV-1
potency.
Conclusions: These results highlight the importance of the length of complementarity between the 3′ terminus of
the mutant tRNALys3 and its target site, and the feasibility of targeting multiple sites within the HIV-1 genome
through mutant tRNALys3. Intervention of the HIV-1 genome conversion through mutant tRNALys3 may constitute an
effective approach for development of novel therapeutics against HIV-1 replication and HIV-1-associated diseases.
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RTion, or the conversion of viral RNA (vRNA) into DNA,
is a key step in the life cycle of HIV-1, and it may take place
before budding as early as in virus producer cells [1,2]. The
reaction is catalyzed by virion-associated reverse transcript-
ase (RT), and initiated with a cellular primer. Although
various primer molecules can be used to initiate RTion
in vitro, all retroviruses employ cellular tRNA [3-9]. DNA* Correspondence: yuanan@hawaii.edu
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reproduction in any medium, provided the orsequence analysis of the HIV-1 provirus reveals tRNALys3
to be the primer for HIV-1 RTion [10,11].
A prerequisite for the initiation of HIV-1 RTion is for-
mation of a properly folded initiation complex of vRNA
and tRNALys3. An 18-nucleotide residue at the 3′
terminus of the tRNALys3 anneals complementarily to
the PBS of vRNA, and primes template-dependent DNA
synthesis [12]. Upon annealing, the primer is extended
and a cDNA is synthesized and termed (−)strand strong-
stop DNA or (−)ssDNA. The (−)ssDNA is released and
anneals to the 3′ terminus of the vRNA, and primes fur-
ther (−)strand DNA synthesis and generates a full-length
(−)strand DNA that is used as a template for (+)strand
DNA synthesis. Along with (−)strand DNA synthesis,. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of two polypurine tracts (PPTs) that resist cleavage: one
immediately upstream of the U3 region (3′-PPT) and
the other at the center of the vRNA (cPPT). These PPTs
are responsible for priming (+)strand DNA synthesis.
The 3′-PPT-primed (+)strand DNA synthesis terminates
at the first modified base in the tRNALys3 molecule and
this product is termed (+)strand strong-stop DNA or (+)
ssDNA [13,14], with the tRNA removed by RNaseH. A
second strand-transfer takes place through annealing of
the (+)ssDNA to the 3′ end of the full-length (−)strand
DNA, followed by (+)strand DNA synthesis. Eventually,
full-length double-stranded viral DNA is formed and in-
tegrates into the host cell genome through the viral inte-
grase protein. For alpha and gamma-retroviruses and
lentiviruses, these obligatory steps in genome conversion
are chaperoned by a major virion protein of the inner
core, the nucleocapsid protein encoded by Gag that
serves as a key cofactor of the RT enzyme [15-21].
Different tRNAs are utilized by various retroviruses.
Although many different tRNAs exist in an infected
cell, each retrovirus is dedicated to its own tRNA
[22-24]. For example, although a single point muta-
tion in the HIV-1 PBS that results from the infre-
quent usage of a low abundant tRNALys5 variant has
been observed [25,26], no spontaneous mutations or
tRNA switches have been reported, except that primer
specificity is less stringent for the murine leukemia
virus [27-29]. Previous tRNA-switch study through
forced selection of a HIV-1 variant that used a non-
self tRNA primer- tRNALys1,2- resulted in severe repli-
cation defect, and reversion to the wild-type PBS-
Lys3 sequence was the most frequent escape route
[30].
Due to specific interactions between HIV-1 and
tRNALys3, antiretroviral strategies targeting this unique
property have been proposed and tested. TRNALys3 deriva-
tives with mutations in their 3′-terminal sequence, were
previously demonstrated to inhibit HIV-1 replication
through induction of aberrant RTion products [31-33].
However, the described antiviral effect was minimal due to
a limited alteration of the sequence. In this study, a series
of mutant tRNALys3s were constructed with extended mu-
tations in the 3′ terminus (up to 18 bp of complementarity
to their targeting sites) with or without a combined A58U
mutation. These mutants were shown to be encapsidated
into progeny HIV-1 virions and reduced their infectivity.
When the mutants were transduced into human
lymphocyte-derived cells using an improved retroviral vec-
tor system [34], the transduced cells showed potent inhib-
ition of HIV-1 replication, with the potency of anti-HIV-1
activity correlating with the complementarity between the
mutated 3′ PBS-binding region of the mutant and its tar-
geting site.Results
Design and cloning of mutant tRNALys3 genes
To strengthen mutant tRNALys3-based anti-HIV-1 activity
through extended mutation of the 3′ terminal sequence,
and targeting other portions of the viral genome, mutant
tRNALys3 genes with various length of mutation targeting
either the TAR, IN-encoding region or Env, with up to 18
bases complementary to their target sites, were constructed
through a fusion-PCR-based strategy (Figure 1A and B).
Among these genes (Figure 1C), an 8-nucleotide mutation
in the 3′ end of Mt8TD resulted in a 12-base pair (bp)
complementarity to the TAR; a 10-nucleotide mutation in
the 3′ end of Mt10TD conferred a 15-bp complementarity
to the TAR. Similarly, an 11-nucleotide mutation in
Mt11TD resulted in a total of 16-bp complementarity to
the TAR, and a 13-nucleotide mutation in Mt13TD pro-
duced an 18-bp complementarity to the TAR. Besides these
mutations, an extra A58U mutation in the Mt11TD-A58U
was included to interfere with the termination of the (+)
ssDNA product as previously reported [31,32]. In addition,
an extra G44C mutation in Mt11TD-G44C was performed
to examine if it was necessary to maintain the native sec-
ondary structure. Finally, two mutants, named Int and Env,
were constructed with a 7-nucleotide mutation resulting in
an 18-bp complementarity to the IN-encoding region and
Env gene respectively. It is noteworthy that the CCA ends
at the 3′ terminus of the wild-type and mutant tRNALys3s
are added post-transcriptionally and are complementary to
the binding sites. The number of mutated bases in each
mutant and its complementarity to the targeting site are
summarized in Table 1.
To facilitate high efficiency and stable expression in hu-
man cells, these mutant tRNALys3 genes were cloned into
an optimized double-copy retroviral vector (Figure 1D).
Due to duplication of the 3′ U3 region during retroviral
vector-mediated transduction of target cells, copy number
of the mutant tRNALys3 gene in transduced cells is theoret-
ically doubled as previously described [35,36].
Retroviral vector-mediated transduction
A prerequisite for functional analysis of the mutant
tRNALys3 is that they are expressed stably at a high level in
human cells. This was accomplished through transduction
of a human T lymphocyte-derived cell line, CEM-SS, with
high-titer retroviral vector stocks. Since the retroviral vector
carries an eGFP gene as a reporter [34], transfected 293T
packaging cells and transduced CEM-SS cells were exam-
ined for eGFP expression (Figure 2A). To generate high-
titer vector stocks for enhanced efficiency of gene transduc-
tion and expression, vector viruses harvested from trans-
fected 293T cells were concentrated through a one-step
ultracentrifugation method and vector titer exceeded 108
IU/mL (Figure 2B). Comparative analysis showed that des-
pite differences in titers of retroviral constructs containing
Figure 1 Construction and retroviral vector-mediated delivery of mutant tRNALys3s. (A) Sequence alignment of primer-template for the
amplification of mutant tRNALys3 through PCR. The Mt11TD is used as an example and mutated bases are shown in bold italic. (B) Schematic
illustration of the fusion-PCR used to amplify full-length mutant tRNALys3 genes. (C) Maps of the mutant tRNALys3s with mutated bases
highlighted in darkened background. (D) Retroviral vector-mediated delivery of the mutant tRNALys3 genes.
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ence on vector production was observed, and the differences
in titers were possibly due to variations among transfections.
When the concentrated vector stocks were used to trans-
duce CEM-SS cells at a multiplicity of infection (MOI) of
100, approximately 90-100% of the cells became GFP posi-
tive on day 3 post infection (pi) through a single transduc-
tion (Figure 2C). This allowed direct use of the transduced
cells, without any selection or cell cloning, for functionalTable 1 Length of mutation and complementarity, and target








Int 7analysis of the mutant tRNALys3 through HIV-1 challenging.
Furthermore, transduction and expression of the mutant
tRNALys3 were confirmed by PCR and RT-PCR (data not
shown).
Inhibition of HIV-1 replication
Anti-HIV-1 activities of the mutant tRNALys3 were firstly
evaluated by examining the relative sensitivity of the trans-
duced CEM-SS cells to HIV-1 infection and the capabilitying sites, of mutant tRNALys3









Figure 2 Transduction of mutant tRNALys3 into CEM-SS cells. (A) Vector production in 293T cells and transduction of CEM-SS cells based on
eGFP expression. (B) Titers of the vector stocks concentrated through ultra-centrifugation. (C) High efficiency transduction of mutant tRNALys3
into CEM-SS cells.
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infecting the mutant tRNALys3-expressing cells with a
replication-competent HIV-1 stock, with relative capability
of the cells to inhibit HIV-1 replication determined using
the median tissue culture infectious dose (TCID50) assay.
As shown in Figure 3A, the transduced cells expressing
various mutants all showed significantly lower TCID50 titers
of the HIV-1 stock compared with the non-transduced cells
or cells transduced with the wild-type tRNALys3 (p < 0.001).
Furthermore, cells expressing mutant tRNALys3 with in-
creasing mutation in their 3′ PBS-binding regions generallyshowed significantly lower TCID50 titers (p < 0.001). Inter-
estingly, cells transduced with the wild-type tRNALys3 did
not significantly change their virus production (p > 0.05).
Cells transduced with Mt11TD-A58U, Mt13TD, Int, and
Env seemed the most refractory to HIV-1 replication, with
significantly higher TCID50 reductions in cells expressing
Mt13TD, Int, and Env than that in cells expressing
Mt11TD-A58U (p < 0.001). Correspondingly, these four
mutants had relatively more potent anti-HIV-1 activities
than the others. To further analyze the anti-HIV-1 effects
of these mutants, the transduced cells were infected with
Figure 3 HIV-1 challenging of CEM-SS cells expressing mutant
tRNALys3s. (A) TCID50 tests. (B) Challenging of cells that showed
potent inhibition of HIV-1 in (A). For cells transduced with the wild-
type tRNALys3, sample collection and analysis did not go beyond day
17 due to massive cells death.
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infected cell cultures were tested for HIV-1 P24 production
every two days for 35 days pi. Figure 3B shows that P24 ac-
cumulated rapidly from day 5 pi in control cells transduced
with the wild-type tRNALys3 and reached a peak concentra-
tion of 1.2 x 107 pg/mL on day 13 pi. In contrast, depend-
ing on the respective mutant expressed in the cells, the
replication kinetics of HIV-1 was delayed by 3–10 days with
significantly decreased production of P24 by 2–3 logs (p <
0.001).
Multiple copy mutant tRNALys3 delivery
Using BLAST, twenty examples of a 234-bp sequence of




larly, multiple copies of tRNALys1 and tRNALys2 genes
were found. Therefore, we hypothesize if mutant
tRNALys3 levels are increased in transduced cells, more
mutant would be encapsidated into progeny HIV-1 vi-
rions upon infection, and the mutant tRNA-mediated
anti-HIV-1 effect will be more effective because of en-
hanced competition against wild-type tRNALys3. To test
this hypothesis, multiple copies of the Mt13TD gene
(one of the mutants with potent anti-HIV-1 activity,
Figures 3A and 3B) were subcloned into the retroviral
vector and subsequently packaged and transduced into
CEM-SS cells.
Although titers of retroviral vectors were not clearly in-
fluenced by insertion of single-copy of the mutant tRNALys3
genes, the retroviral constructs carrying multiple copies of
the Mt13TD gene showed an apparent pattern of signifi-
cant decrease in titers (p < 0.001) (Figure 4A). The vector
titer from the triple copies of Mt13TD construct dropped
from 3.03 ± 0.25 × 106 IU/mL to 2.25 ± 0.35 × 105 IU/mL
compared with that of the construct carrying single-copy of
Mt13TD– a 13-fold decrease, which was also seen where
the titer derived from the construct with 12 copies of the
Mt13TD gene dropped to 3.72 ± 0.12 × 103 IU/mL. To
overcome the challenge due to decreased titers from these
vector constructs, clones of transduced cells were obtained
through a limiting-dilution method and tested for viral in-
hibition with replication competent HIV-1.
In spite of marked variations among different clones,
Figure 4B shows that cells transduced with the construct
carrying 3 copies of Mt13TD showed lower TCID50 ti-
ters compared to cells transduced with single-copy of
the gene. Consistently, cells transduced with the con-
struct carrying 6 copies of the gene generally showed
lower TCID50 titers than cells transduced with 3 copies.
Furthermore, cells transduced with the construct carry-
ing 12 copies showed the lowest TCID50 titers, with ex-
ception of two clones.
Based on the results from the TCID50 test, two of the
clones transduced with the 12-copy construct were further
evaluated by challenging with HIV-1 at MOIs of 0.1 and
1.0 respectively. As shown in Figures 4C and 4D, these two
clones showed significant reduction of HIV-1 replication
than cells transduced with a single copy of the same gene
or the wild-type tRNALys3, especially the latter (p < 0.001).
When challenged at MOI 1.0, peak production of P24 from
cells transduced with the wild-type tRNALys3 occurred at
day 6 pi with massive cell death, and P24 production de-
creased sharply following that time point. When these con-
trol cells were infected at MOI 0.1, the peak production of
P24 occurred on day 12 pi, with the absolute concentration
of the peak level 1.26 times higher than that of the cells
Figure 4 Characterization of CEM-SS cells transduced with retroviral constructs carrying multiple copies of the Mt13TD gene. (A)
Comparison of titers of vector preparations. (B) TCID50 tests on cloned cells. Numbers of 3, 6, 9 and 12 correspond to copies of the gene in the
retroviral constructs used to transduce the cells. NT, non-transduced. (C) Based on results in (B), two clones of cells transduced with Mt13TD-12,
namely No. 3 and No. 5 respectively, were challenged with HIV-1 at MOI of 1.0. Cells transduced with vectors containing one copy of either the
wild-type tRNALys3 or the Mt13TD gene were challenged and sampled simultaneously as controls. (D) The same type of cells as in (C) were
challenged at a lower MOI of 0.1 and sampled.
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1.0, the cells transduced with the vector carrying single-
copy of Mt13TD accumulated concentration of P24 2 logs
lower with occurrence of the peak level delayed to day 9 pi.
Following that time point, the P24 level remained relatively
stable with a slight decrease. Similarly, when challenged at
a lower MOI of 0.1, the P24 accumulated slower with con-
centrations greater than 2 logs lower compared with that of
the cells transduced with the wild-type tRNALys3. In
addition, the occurrence of peak concentration of P24 wasdelayed by 3 weeks, and the P24 levels remained relatively
stable with only a slight increase following that time point.
In respect of challenging cells transduced by the con-
struct carrying 12 copies of the Mt13TD gene at both
MOIs, the data were drastically different. As shown in
Figure 4D, in cells infected at MOI of 0.1, P24 accumu-
lation occurred significantly slower compared to that in
cells transduced with the wild-type tRNALys3 gene, with
3 logs lower concentration of P24 at its peak, and the
P24 concentrations remained fairly stable. Moreover,
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replication compared to cells transduced with the vector
containing single-copy of the Mt13TD gene. When
challenged at MOI 1.0, the peak level of P24 was more
than 2 logs lower compared to that of cells transduced with
the wild-type tRNALys3 gene and 4 times lower than that of
cells transduced with a single-copy Mt13TD (Figure 4C).
Once the peak concentration of P24 occurred, P24 levels
dropped to one log lower compared to that of cells trans-
duced with a single-copy of Mt13TD.
Potential adverse impact by mutant tRNALys3
To determine whether transduction and expression of
mutant tRNALys3 resulted in any adverse impact on tar-
get cells, transduced cells were examined for their
growth kinetics and morphology where no obvious alter-
ation was found at different passage numbers (data not
shown). Subsequent MTT assays also found no statisti-
cally significant difference between non-transduced cells
and those transduced with mutant tRNALys3s (P > 0.05)
(Figure 5A). To rule out the possibility that mutant
tRNALys3 may interfere with the translation machinery
in transduced cells, expressions of two reporter genes,
luciferase [37] and hTNFR-Fc [38], were examined.Figure 5 Cytotoxicity assay. (A) MTT tests on the growth and viability of
as in (A) were infected with the same amount of lentiviral vector carrying
as in (A) were infected with the same amount of lentiviral vector carryingFigure 5B and C indicate that expression of these re-
porter genes were not significantly influenced by the
transduction and expression of mutant tRNALys3
(P > 0.05).Encapsidation and priming assay
Analysis was performed at the molecular level to test the
hypothesis that the improved anti-HIV-1 activities of the
mutant tRNALys3s were conferred through improved
priming or directing RTion of HIV-1 to their targeting
sites rather than the normal PBS. Retroviral plasmid
containing the mutant tRNALys3 gene was respectively
co-transfected with a defective HIV-1-based vector system,
with RT-PCR using RNAs extracted from the HIV-1 virions
harvested from the co-transfections employed to examine
encapsidation of the mutant tRNALys3s. As shown in
Figure 6A, when the RT-PCR products were separated
through 2.0% agarose gel electrophoresis, DNA bands of 76
bp corresponding to the size of the mutants were detected.
When the HIV-1-based packaging plasmid was omitted
from the co-transfections, the mutants were not detected
under the same experimental conditions. This indicated
that the mutant tRNALys3 genes were expressed from theCEM-SS cells transduced with mutant tRNALys3s; (B) Cells transduced
the luciferase gene and tested for luminescence; (C) Cells transduced
the hTNFR-Fc gene and tested for sTNFR-Fc in the supernatant.
Figure 6 Mutant tRNALys3 encapsidation assay. (A) Detection of mutant tRNALys3 in HIV-1 virions that were generated through co-transfection
of plasmids encoding a HIV-1-based vector system and a retroviral plasmid carrying the mutant tRNALys3 gene. +, with packaging plasmid;
-, without packaging plasmid. (B) Titers of vectors generated through co-transfections as in (A). Titers were determined on CEM-SS cells.
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HIV-1 particles.
In addition, their relative anti-HIV-1 activities were evalu-
ated through a one-replication-cycle assay with replication-
defective HIV-1-based vectors harvested from the co-
transfections. This was accomplished through titration of
the vectors in CEM-SS cells. Figure 6B shows that titers of
the HIV-1-based vectors were significantly reduced when
they were prepared through co-transfection with the mu-
tant tRNALys3s (p < 0.001), with 15-20-fold reductions when
the vector system was co-transfected with Mt11TD-A58U,
Mt13TD, Env, and Int respectively. Moreover, a significant
difference in the level of reduction was demonstrated, with
a pattern consistent with the previous TCID50 assay
(Figure 3A).
To characterize the efficiency and specificity of mutant
tRNALys3-primed HIV-1 RTion, the mutant tRNALys3-con-
taining HIV-1 virions were used to infect CEM-SS cells,
with DNAs extracted from the infected cells and subjected
to PCR amplifications. Two primers, the forward primerspecific to a site in the U3 region of HIV-1 3′ LTR of the
RTion product following the first strand transfer event and
the reverse primer specific to the mutated PBS-binding re-
gion of respective mutant tRNALys3, were used for the am-
plifications (more detail in Methods). For HIV-1 virions
containing mutant targeting the TAR, PCR product ampli-
fied from RTion products primed from the TAR would be
226 bp in size. In case that the mutant tRNALys3 primes
RTion from the normal PBS as previously reported [33],
another PCR product with the expected size of 395 bp will
be generated. Moreover, amplification efficiencies of the
products would be approximately the same since the same
primers were used and the PCR products are similar in size.
Consequently, if both products were amplified, concentra-
tions of the end products would reflect the relative starting
amount of the templates. Figure 7A shows that Mt8TD
made a fair amount of non-specific priming from the PBS,
as indicated by the relative intensity of the 395-bp band to
that of the 226-bp band. When the length of mutations was
extended in other mutants, such as Mt10TD, non-specific
Figure 7 Priming assay. (A) Amplifications from the products of RTion primed through mutant tRNALys3s targeting the TAR. +, heat-inactiviation
of HIV-1-based vectors before infection; –, no heat-inactiviation. (B) Amplifications from the products of HIV-1 RTion primed through mutant
tRNALys3s targeting the IN-encoding region and Env gene respectively. CTRL, CEM-SS cells were infected with heat-inactivated HIV-1-based vector
and RTion products were amplified using the combined primers for detection of both types of the RTion products.
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395-bp band decreased notably. This tendency continued
with Mt11TD. In case of Mt13TD that contained 18 bp
complementarity to the TAR (Figure 1C and Table 1), the
product that would reflected non-specific priming of RTion
from the PBS was nearly non-detectable.
Similarly, priming of HIV-1 RTion by two of the
mutants that target the IN-encoding region or Env
gene was examined and characterized. Two PCR reac-
tions were employed for each mutant (details speci-
fied in Methods). After separation of the PCR
products, robust DNA bands amplified from the
RTion products primed from their targeting sites were
detected. In contrast, the PCR product that would re-
flect the RTion product primed non-specifically from
the PBS was not detectable (Figure 7B).
Quantification of transduction and expression of mutant
tRNALys3
Due to significant variations in the anti-HIV-1 activities of
different cell clones transduced with the multiple-copyMt13TD constructs (Figure 4B), it was speculated that
these variations might be caused by difference in the ex-
pression of Mt13TD among different clones. Real-time
PCR and RT-PCR were employed to quantify the copy
number of the Mt13TD gene and the relative expression
level of Mt13TD versus that of the wild-type tRNALys3.
Table 2 shows copy numbers of the Mt13TD gene in cells
transduced with the multiple-copy constructs were largely
determined by the vector constructs used, with exception
for one cell clone transduced with vectors carrying either 3
or 9 copies of Mt13TD respectively, and two cell clones
transduced with the construct carrying 12 copies of genes.
However, levels of Mt13TD varied notably among cells
transduced with the same vector construct. Among cell
clones transduced with different multiple-copy constructs,
relative expression of Mt13TD varied even more dramatic-
ally (Table 3). In particular, expression level of Mt13TD was
less than that of the wild-type tRNALys3 in all cell clones re-
gardless of the copy number of Mt13TD that was intro-
duced into the cells. However, cell clones transduced with
more copy numbers of Mt13TD generally tended to have
Table 2 Quantification of copy number of Mt13TD in cells
transduced with the multiple-copy vector constructs
TD-1 TD-3 TD-6 TD-9 TD-12
1 2.14 ± 0.17 6.08 ± 0.17 12.14 ± 0.23 18.05 ± 0.26 24.11 ± 0.19
2 5.98 ± 0.26 12.06 ± 0.28 18.03 ± 0.27 24.1 ± 0.27
3 4.07 ± 0.25 12.02 ± 0.13 18.04 ± 0.16 23.95 ± 0.23
4 6.07 ± 0.08 12.05 ± 0.24 18.07 ± 0.16 24.01 ± 0.13
5 6.04 ± 0.11 12.19 ± 0.17 17.99 ± 0.12 23.98 ± 0.17
6 6.07 ± 0.1 11.99 ± 0.26 13.08 ± 0.23 1.98 ± 0.17
7 6.02 ± 0.13 11.84 ± 0.47 18.06 ± 0.3 10.05 ± 0.09
8 6.01 ± 0.1 11.97 ± 0.1 18.0 ± 0.12 23.98 ± 0.17
9 5.98 ± 0.18 12.06 ± 0.25 18.03 ± 0.18 24.05 ± 0.08
10 6.06 ± 0.11 12.05 ± 0.11 18.1 ± 0.05 24.04 ± 0.15
11 6.09 ± 0.03
12 5.95 ± 0.08
Note: TD-1,3,6,9,12, retroviral vector carrying 1,3,6,9 and 12 copies of Mt13TD
gene respectively; 1–12, cell clones derived from transduced cells with the
multiple-copy retroviral constructs.
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HIV-1 activities as evaluated in previous tests (Figure 4B).Discussion
Rationale for designing the mutant tRNALys3
tRNAs are an essential part of the protein translation
mechanism in cells and are recognized by many intracellu-
lar proteins including the 5′ and 3′ tRNA processing en-
zymes [39] and tRNA aminoacyl transferases [40,41].
Retroviruses selectively encapsidate tRNAs as primers,Table 3 Relative expression of Mt13TD versus wild-type
tRNALys3 in cells transduced with multiple-copy vector
constructs
TD-1 TD-3 TD-6 TD-9 TD-12
1 6.91 ± 0.65 7.48 ± 0.79 20.74 ± 0.83 22.7 ± 0.41 27.01 ± 0.13
2 18.32 ± 0.63 17.4 ± 1.18 23.11 ± 0.34 57.87 ± 0.41
3 3.98 ± 0.26 15.48 ± 0.43 45.42 ± 0.33 82.35 ± 0.78
4 20.16 ± 0.81 22.66 ± 0.32 42.48 ± 0.38 48.68 ± 0.45
5 20.71 ± 0.81 26.15 ± 0.35 24.72 ± 0.18 77.26 ± 0.87
6 19.38 ± 1.13 48.74 ± 0.35 6.8 ± 0.39 0 ± 0
7 18.33 ± 1.22 43.43 ± 0.62 65.78 ± 0.76 4.11 ± 0.24
8 22.79 ± 0.41 41.1 ± 0.4 40.03 ± 0.45 54.37 ± 0.65
9 24.89 ± 0.23 38.54 ± 1.26 39.76 ± 0.64 55.74 ± 0.55
10 23.19 ± 0.35 23.14 ± 0.18 28.3 ± 1.03 35.18 ± 0.33
11 19.14 ± 0.83
12 22.9 ± 0.15
Note: the expression level of wild-type tRNALys3 is arbitrarily set as 100%, and
the relative percentages of expression of Mt13TD are shown.resulting in an increased concentration of certain tRNAs
inside the virions compared with the cytoplasm of the in-
fected cells [42-45]. For the selective incorporation of
tRNALys into HIV-1, both the vRNA and interactions be-
tween the tRNALys and vRNA are dispensable since viral
particles lacking an RNA genome are still able to incorpor-
ate the wild-type set of tRNALys [45]. However, selective
packaging of tRNALys is affected in virions lacking a func-
tional RT domain [45-47], and the centrally located thumb
subdomain of RT is indispensable [48].
In HIV-1 virions, all tRNALys isoacceptors are en-
riched. The ratio of tRNALys3 versus tRNALys1,2 are the
same in cells and virions, with approximately 8 and 12 mol-
ecules per particle respectively [49]. The tRNALys molecules
are encapsidated during particle assembly via interactions
between the Gag-Pol precursor and a protein complex
composed of the cellular lysyl-tRNA synthetase (LysRS)
and the Gag protein [45,48,50-52]. Changing the intracellu-
lar levels of LysRS, by either overexpression or siRNA-
mediated silencing, results in a concomitantly altered level
of tRNALys in virus particles. This suggests that LysRS may
be the limiting factor for tRNALys packaging [53-55]. The
presence of other tRNA synthetases in HIV-1 virions has
also been analyzed [51,56], with only LysRS detected
among eight synthetases screened. Approximately 20–25
LysRS and 20 tRNALys molecules are present per virus par-
ticle, indicating an approximately equimolar stochiometry
[51]. These previous studies provided the supporting foun-
dation for this study of anti-HIV-1 replication by designing
and constitutive expression of the mutant tRNALys3.
In designing the mutant tRNALys3, we extended the
length of mutations in the 3′ terminal PBS-binding region
to enhance their binding specificity and efficiency of direct-
ing the RTion of HIV-1 to new targeting sites. In addition,
corresponding mutations to maintain the natural secondary
structure of tRNALys3 were made (Figure 1C) with the nat-
ural promoter and terminator sequences needed for tran-
scription and post-transcriptional processing maintained.
Integrity of the anti-codon domain that is important for in-
teractions between the tRNALys3 and LysRS was also kept
intact. To facilitate efficient transcription and processing of
the mutant tRNALys3 genes, the 5′and 3′ flanking se-
quences that were derived from three of the most efficiently
expressed cellular tRNALys3 loci [57] were included. Conse-
quently, except for the mutations mentioned, the remaining
parts of the tRNALys3 were not altered (Figure 1C). Because
both vRNA and interactions between tRNA and vRNA are
dispensable in the tRNALys3 encapsidation process [45], en-
capsidation of the mutant tRNALys3 is unlikely to be influ-
enced, as confirmed by RT-PCR tests (Figure 5A).
Improved inhibition of HIV-1 replication
We report that mutant tRNALys3 with extended mutations
in the PBS-binding region were effectively expressed and
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ected the RTion of HIV-1 to targeting sites with improved
specificity and efficiency, which concomitantly heightened
the inhibition of HIV-1 replication. Furthermore, besides
the TAR, sites downstream of the PBS such as the IN-
encoding region and Env gene could be effectively targeted.
Moreover, enhanced anti-HIV-1 activity was observed when
these mutations were combined with a previously reported
A58U mutation [32]. This indicates the mutations in the 3′
PBS-binding region conferred anti-HIV-1 activities in a dif-
ferent mechanism from that of the A58U mutation, which
could give rise to an additive anti-HIV-1 effect.
Transduction and expression of mutant tRNALys3
For efficient delivery and expression of the mutant
tRNALys3 in human cells, a retroviral vector system was
optimized [34] and employed. The retroviral vector was
used because it does not process inherent capability of
inhibiting HIV-1 replication as previously demonstrated
[32,33]. This offers an advantage for the analysis of anti-
HIV-1 activities compared to a HIV-1-based vector that
has been previously shown to process potent inherent
inhibition of HIV-1 replication [58]. Furthermore, titers
of the retroviral vectors with a single-copy of the mutant
tRNALys3s were not significantly affected, indicating the
mutants did not interfere with infectivity of the retro-
viral vector. Although titers of vector preparations were
significantly reduced when multiple copies of Mt13TD
were introduced, such reduction might not be directly
related the mutant tRNALys3. Rather, a more plausible
explanation is the insertion of a large DNA fragment in
the LTR that might hinder vRNA processing and trans-
duction of target cells as previously reported with lenti-
viral vectors [59]. Rather than being used as a delivery
tool, an HIV-1-based vector system was employed for
the one-replication-cycle infection assay and provided
supplemental evidence to those obtained through HIV-1
challenging tests. When the mutant tRNALys3 constructs
were co-transfected with the HIV-1-based vector system,
vector titers were significantly reduced by more than
one log for four of the mutants tested (Figure 6B). These
results indicates a marked hindrance of the RTion
process within the HIV-1 virions, which is consistent
with potencies of the anti-HIV-1 activities of the mu-
tants as determined by TCID50 and HIV-1 challenge
tests (Figures 3A and 3B).
Transduction of multiple copies of mutant tRNALys3
Naturally, all tRNALys isoacceptors are enriched in the
HIV-1 virions with the same the ratio of tRNALys3 versus
tRNALys1,2 between cells and virions [49]. In addition,
there are multiple copies of these genes in the human
genome. To improve the encapsidation of mutant
tRNALys3 through increasing its concentration intransduced cells, we hypothesized that delivery of mul-
tiple copies of the gene may further boost its anti-HIV-1
effects. As anticipated, transduction of multiple copies of
the Mt13TD gene into CEM-SS cells resulted in de-
creased HIV-1 replication (Figures 4B and 4C). Further-
more, we examined the copy numbers of Mt13TD in
these clones and the expression level of Mt13TD as
compared to that of its wild-type counterpart. We dem-
onstrated the potency of inhibition of HIV-1 replication
in the cell clones was more closely determined by the
relative level of expression of Mt13TD, rather than by
the copy number of this gene that was introduced into
the cells (Figure 4B and C and Tables 2 and 3). As for
the variations in expression of the gene, it could be at-
tributed to the position effect of the integration site. For
the four clones with less copies of Mt13TD as expected,
we hypothesize that some irregular event such as recom-
bination was the cause, since retroviral vectors are un-
stable with repeat sequences [60]. Nevertheless, none of
these is directly associated with the mutant tRNALys3
but are more likely to be associated with the delivery
system. Future optimizations on the vector system or
change of the delivery vector may possibly resolve these
issues.
Implications of targeting multiple sites
Due to high mutation rates of HIV-1, drug resistance
mutations constitute a major concern that confronts
current antiretroviral strategies. When mutant
tRNALys3 targeting a single site of the HIV-1 genome
is expressed, potential viral resistance is possible
through mutations in the PBS to acquire complemen-
tarity to the mutant tRNALys3 or in the site being tar-
geted to reduce its complementarity to the mutant
tRNALys3. Therefore, the mutant tRNALys3-mediated
anti-HIV-1 strategy would be more effective if mul-
tiple sites within the HIV-1 genome could be tar-
geted. To test this concept, two tRNALys3 mutants
targeting the IN-encoding region and Env gene, re-
spectively, were tested. These targeting sites were se-
lected because only a 7-base substitution in the 3′
PBS-binding region of the tRNALys3 allowed an 18-bp
complementarity to the sites respectively (Figure 1A).
RTion priming tests indicated that these mutants
were as effective as others targeting the TAR
(Figure 7B) with high specificity and efficiency, show-
ing no detectable priming activity from the PBS. Both
TCID50 assay and HIV-1 challenging tests indicated
these mutants could lead to inhibition of HIV-1 infec-
tion to similar potencies as Mt13TD (Figure 3A and
3B). These findings clearly suggest that the mutant
tRNALys3-mediated inhibition of HIV-1 replication is
not limited to targeting sites upstream the PBS and
other portions of the vRNA could be effectively
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taneous delivery of multiple mutants that target vari-
ous portions of the vRNA, which would provide a
strong genetic barrier for spontaneous evolution of
resistant HIV-1 genome.
Proposed anti-HIV-1 mechanisms through mutant
tRNALys3
Upon HIV-1 infection of cells that express mutant
tRNALys3, both wild-type and mutant tRNALys3 are encapsi-
dated into the progeny virions and are capable of initiating
RTions from the PBS and the targeting sites, resulting in
aberrant RTion products. Furthermore, due to the
RNaseH-mediated degradation of vRNA, a gap between
the site being targeted and the PBS is generated. Conse-
quently, integrity of the viral genome is disrupted. This
would lead to abortion of the genome conversion and non-
productive infection of the cell (Figure 8). Consequently,
replication cycle of the virus is bleached.
However, due to competition between the wild-type
and mutant tRNALys3s and presence of high concentra-
tions of the wild-type tRNALys3 in the cell, some progeny
virions may carry the natural set of tRNALys without
mutant tRNALys3 where infectivity of this type of pro-
geny virus is not affected. In addition, priming of RTion
by the wild-type tRNALys3 and complete synthesis of the
(−)ssDNA before disruption of the viral genome through
RTion primed by the mutant tRNALys3 also may take
place in some virions due to encapsidation of insufficient
amount of mutant tRNALys3. This will lead to successful
conversion of the viral genome and productive infection
of the cell. These possibilities may explain why CEM-SS
cells transduced with mutant tRNALys3 showed signifi-
cantly reduced support to HIV-1 replication but did not
completely eliminate the viral infection. However, impact
of these possibilities can be minimized through increas-
ing expression/concentration of the mutant tRNALys3 in
target cells by transduction of multiple copies of the
gene, or simultaneous transduction of multiple mutants
that target various portions on the HIV-1 genome.
Conclusions
We demonstrated that the potency of anti-HIV-1 activity
of the mutant tRNALys3 correlated with the length of
complementarity between the mutated PBS-binding
region and the targeting site, and we showed that in-
creasing the concentration of mutant tRNALys3 in cells
through transduction of multiple copies of the gene fur-
ther augmented its anti-HIV-1 potency. We also targeted
effectively various sites widely distributed in the HIV-1
genome, which would provide an effective means of
fighting the evolution of resistance HIV-1 mutants. Be-
cause of the specific associations between HIV-1 and
tRNALys3, off-target side effects that are associated withother anti-HIV-1 approaches can be avoided, which may
offer significant advantages over conventional anti-
HIV-1 methods such as antisense RNA or RNA interfer-
ence. Inhibition of HIV-1 replication through mutant
tRNALys3 may represent a novel and effective gene ther-
apy approach against HIV-1-associated diseases.
Methods
Mutant tRNA construction and cloning
Mutant tRNALys3s with various lengths of mutations in
their PBS-binding region that targeted new sites in
HIV-1 genome were generated through PCR-based mu-
tagenesis as previously described [33] with minor modi-
fications. Briefly, a primer including the coding sequence
of tRNALys3 and the desired mutations, as specified in
Table 4, was synthesized (integrated DNA techniques,
IDT) and used as a template for PCR amplification with
primers FatRNA and RatRNA. The PCR product was
named fragment A. A second PCR used primers
FbtRNA and RbtRNA and human genomic DNA ex-
tracted from 293T cells as template, with the PCR prod-
uct named fragment B. A third fusion-PCR used primers
FatRNA and RbtRNA, with fragments A and B as tem-
plates, and gave rise to a 234-bp fragment. Using
primers FatRNA and RbtRNA, the wild-type tRNALys3
gene was amplified from human genomic DNA, and a
mutant tRNALys3 gene containing the A58U mutation
was amplified from plasmid pPPT-PGK-A58U [31]
(a kind gift from Dr. Planelles Vicente, University of
Utah). The amplified genes were subsequently cloned
into the SnaB I restriction site of the plasmid pSV-N2A-
GFP [34].
To construct the vector with three copies of Mt13TD,
the plasmid with one copy was first digested with Bgl II
and blunted with DNA polymerase I Klenow fragment
to insert the second copy, and the resultant plasmid was
digested with Sac II and blunted to insert the third copy.
To construct the vector with six copies, the plasmid with
three copies was digested with Mlu I and blunted and
inserted with a three-copy fragment cut from the same
plasmid with Nhe I and blunted with Klenow fragment.
To construct the vector with nine copies, the plasmid
with six copies was digested with Mlu I and blunted,
and inserted with the three-copy fragment. To construct
the vector with twelve copies, the plasmid with nine
copies was digested with Mlu I and blunted, and
inserted with the three-copy fragment. To prevent self-
ligation, linearized plasmid DNAs were treated with calf
intestinal alkaline phosphatase (New England Biolabs,
NEB) as previously described [61] before ligations.
Delivery of mutant tRNALys3 into target cells
Retroviral vector were packaged and used to transduce
CEM-SS cells as previously described [34,62]. Detection
Figure 8 Proposed mechanisms of disruption of genome
conversion of HIV-1. step 1, tRNALys3s anneal vRNA and initiate
RTions, with vRNA degraded by RNaseH; step 2, strand transfer of (−)
ssDNA-tRNALys3; step 3, (−)strand DNA synthesis proceeds, with
vRNA degraded except for PPTs; step 4, (−)strand DNA synthesis
proceeds to 5′end of vRNA; step 5, (+)strand DNA synthesis starts
with complementary (mutated) PBS copied from tRNALys3; step 6:
tRNALys3 is removed, and the second strand transfer fail to proceed.
(A) Mechanisms by mutant tRNALys3 targeting the TAR. Both
tRNALys3s are encapsidated and initiate RTions, generating two
products. One primed by the mutant contain a short 5′ end of the R,
but lack sequence from the 3′ end to the PBS (step 1). Following
strand transfer, if it happens, synthesis of (−)ssDNA strand proceeds
and degrades vRNA (step 3). Simultaneously wild-type tRNALys3-
primed RTion proceeds and degrades vRNA (steps 2–6).
Consequently, the integrity of vRNA is disrupted and the second
strand transfer cannot proceed (step 6). For the (−)ssDNA primed by
the wild-type tRNALys3, strand transfer may be blocked or proceed at
lower efficiency due to lack of 5′ end of the R, and extension of the
(−)DNA synthesis cannot proceed due to disrupted integrity of vRNA
(step 3). (B). Mechanisms by mutant targeting sites downstream PBS.
The mutant targeting the IN-coding region is taken as an example.
Similar to (A), both tRNALys3s initiate RTions with vRNA degraded.
The (−)ssDNA primed by mutant lack sequences beyond the PBS
(step 1), which disrupts strand transfer. Extension of the (−)stand
DNA synthesis by the (−)ssDNA primed by the wild-type tRNALys3
cannot proceed (step 4) due to disrupted integrity of vRNA (step
1&2), which further disrupts the second strand transfer (step 6).
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by PCR with primers specific to the mutated regions of
the mutants and genomic DNA extracted from the cells
as template. Primers (F) 5′-TAGACCATAGCTCAG-3′
and (R) 5′-TGGTTAGACCAGATC-3′ were used for de-
tection of the mutants targeting the TAR; primers (F)
5′-TTTATTATAGCTCAGTC-3′ and (R) 5′-TGGGTT
TATTACAGGG-3′ were used for detection of the mu-
tant targeting the Env gene; and primers (F) 5′-
GGTGGGGTAGCTCAG-3′ and (R) 5′-TGGGGGTGG
AGGTGG-3′ were used for detection of the mutant tar-
geting the IN-encoding region. To examine expression
of the mutant tRNALys3s, RT-PCR was used with the
same primers. Briefly, total RNA was extracted from
transduced CEM-SS cells using the acid guanidinium
isothiocyanate/phenol-chloroform method [63]. First
strand synthesis was done using MoMuLV RT (NEB)
following the vendor’s manual with 100 ng antisense pri-
mer specific to the gene to be detected. One microliter
from the reaction was used as template for PCR amplifi-
cation, with the PCR product separated with 2% agarose
gel and visualized through ethidium bromide staining.
Cells and viruses
293T cells and CEM-SS cells were routinely maintained
and split as previously described [62]. Replication com-
petent HIV-1 virus was generated through transient
transfection of 293T cells with plasmid pHIV-thy (from
Dr. Planelles) and used for HIV-1 challenging tests.
Table 4 Primers used for PCR-based amplification of mutant tRNALys3 derivatives
Primer
name

















Note: mutated bases are shown in bold italic.
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cells, and virus-containing supernatant was collected on
day 9 when maximal amount of syncytia were observed,
aliquoted in 1.0 mL and stored at −80°C until used.Cytotoxicity tests
MTT assay [64] was performed as previously described
[38] with minor modifications. Briefly, cells non-
transduced or transduced with mutant tRNALys3 were
inoculated in triplicates at 1.0 × 104 cells/well in 96-well
plate in 100 μl RPMI-1640 medium with 2% FBS includ-
ing three wells without cell as blanks, and cultured at 37
C with 5% CO2. Each well was treated with 10 μl MTT
(5 mg/mL) for 4 h at 37 C on day 3 post inoculation,
followed by addition of 100 μl DMSO. Plate was gently
swirled and left with cover in the dark for 4 hours at
room temperature. To measure the absorbance, plate
was read at 570 nm using a microplate reader (Beckman
Coulter AD340). The optical densities (OD) were com-
pared and used for evaluating cell growth and viability.
A lentiviral vector expressing the firefly luciferase gene
and eGFP was constructed through cutting the cDNA of
luciferase from pNL-CMV-Luc (from Dr. Planelles) with
Xho I and Mlu I, and ligated into the plasmid pHR-
hTNFR-Fc-eGFP [38] that was cut by Xho I and Asc I.
Resultant plasmid, named pHR-luc-eGFP, and pHR-
hTNFR-Fc-eGFP were respectively packaged as previ-
ously described [65], and used to infect 1.0 × 105
CEM-SS at MOI 10.0. On day 7 following infection,
supernatant of the cultured cells were collected and ex-
amined for sTNFR-Fc expression as previously described[38]. Test for luciferase activity was done with the dual
luciferase assay kit (Promega). Following the vendor’s
manual, cell lysates were prepared from 1.0 × 106 cells
using 200 μl 1× PLB through the passive lysis method,
and 20 μl from each lysate were sampled for the test. Lu-
minescence was measured in a Turner luminometer-96
(Turner Designs, Sunnyvale, CA). The readings, counts
per second (CPS), were used to evaluate luciferase
activities.TCID50 assay
TCID50 assay was performed as previously described
[33] with minor modifications. Briefly, CEM-SS cells at
the exponential growth stage were seeded into 96-well
plates at 5 × 103 cells/well in 100 μL RPMI1640 medium
with 10% heat-inactivated fetal bovine serum (FBS). The
HIV-1 virus stock was serially diluted 10-fold with
RPMI1640 medium without serum, and 100 μL/well of
each virus dilution was inoculated into 4 wells with cells
along with control wells receiving the same amount of
virus-free medium. The infected cells were examined
daily for syncytia formation and TCID50 readings were
determined on day 15 pi.HIV-1 challenge and P24 assay
HIV-1 challenge and P24 assay was done as previously
described [58] with minor changes. Briefly, 4 × 105 cells
transduced with mutant tRNALys3 in the exponential
growth phase were pelleted with a bench top centrifuge
at 3000 rpm for 3 minutes, washed once with 1.0 mL
RPMI1640 medium without serum, pelleted, and then
Table 5 Primers used for priming assay
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sired MOI. After adsorption at 37°C for 90 minutes, cells
were pelleted and washed for three times with 1.0 ml
RPMI1640. After the third washing and pelleting, super-
natant was discarded. Cells were resuspended in 6.0 mL
RPMI1640 medium containing 10% heat-inactivated
FBS, and incubated at 37°C in a T-25 flask. Every 2 or 3
days following the infection, 0.5 mL of cell-free super-
natant was collected from the flasks and used for P24
assay through an antigen capture enzyme-linked im-
munosorbent assay (ELISA) (Coulter Immunology,
Hialeah, FL).
Mutant tRNALys3 encapsidation assay
To confirm encapsidation of mutant tRNALys3, retroviral
vector plasmid containing the mutants were respectively
co-transfected with a three-plasmid HIV-1-based vector
system [62]. For negative controls, transfections omitting
the packaging plasmid were performed. Supernatant
conditioned by transfected cells were collected and ti-
trated on CEM-SS cells. In addition, 35 mL supernatant
was concentrated into 0.1 mL through an ultracentrifu-
gation method [34]. Viral RNA was extracted using the
QIAamp viral RNA mini kit (Qiagen) with detection of
mutant tRNALys3 from the RNA extractions performed
through RT-PCR using the same primers as used for the
detection of the mutants form transduced CEM-SS cells.
Priming assay
To characterize the specificity and efficiency of RTion
primed by mutant tRNALys3, a competitive PCR-based
method was employed. Briefly, HIV-1-based vectors with
mutant tRNALys3 were prepared and concentrated as
previously described, with 0.1 ml of concentrated vector
used to infect 1.0 × 106 CEM-SS cells. For negative con-
trols, infections were done with the same amount of vec-
tor that was inactivated by incubation at 65°C for 60
minutes. Infected cells were incubated at 37°C for 12
hours in 4.0 ml RPMI1640 with 10% FBS, and then pel-
leted and used for DNA extraction as previously de-
scribed [34]. Twenty nanogram of extracted DNA was
used as template for PCR amplification, with primers
specified in Table 5. For mutants that targeted the TAR,
we used the forward primer named F-tRNA that is spe-
cific to the U3 region of HIV-1 3′ LTR (nucleotides
7354–7377 in the transfer plasmid of the HIV-1-based
vector system [62]), and a reverse primer specific to the
mutated region of each mutant. Where RTion is initiated
from the TAR, the PCR products is amplified from the
(−) and (+) ssDNAs generated (as illustrated in steps 3–
5 in Figure 8), which is 226 bp in size. In case where
RTion is initiated from the PBS as previously reported
[33], the PCR product is 395 bp in size. For mutants that
targeted the IN-encoding region and Env generespectively, two PCR reactions were performed for each
mutant. The forward primer, F-tRNA, and a reverse pri-
mer specific to the mutated PBS-binding region of the
mutant, were used to amplify and detect the (−) and (+)
ssDNAs primed from the PBS with the PCR product 395
bp in size. To detect the (−) and (+) ssDNAs primed
from their targeting sites, forward primers, named as
F-Env and F-Int that were specific to a site 226 bp
upstream of their targeting sites, and the same reverse
primer, were used. The PCR product is 226 bp in size.
Following amplifications, the PCR products were sepa-
rated and visualized as previously described.
Real-time PCR and RT-PCR
To examine copy numbers of the Mt13TD gene in cells
transduced with the multiple-copy vector constructs,
real-time PCR was employed using 20.0 ng genomic
DNAs extracted from the cells as template. Primers
specific for Mt13TD were (F) 5′-TAGACCATAGCT-
CAGTCGGTAGAGCATCAG-3′and (R) 5′-TGGTTA-
GACCAGATCTGATTGAAAGATCG-3′, and primers
specific the wild-type tRNALys3 were (F) 5′-GCCCGGA-
TAGCTCAGTCGGTAGAGCATCAG-3′ and (R) 5′-
TGGCGCCCGAACAGGGACTTGAACCCTGG-3′. To
examine the relative expression of Mt13TD versus wild-
type tRNALys3, total cellular RNAs were extracted from
the cells, with 2.0 μg RNAs used for RTion as pre-
viously mentioned, using the wild-type tRNALys3- and
Mt13TD-specific reverse primers. Subsequently, copy
numbers of the wild-type tRNALys3 and Mt13TD in 1.0
μl of the RTion were respectively determined through
real-time PCR.
For real-time PCR analysis, 1.0 μl of genomic DNAs or
cDNA were amplified in triplicates in 25 μl reaction vol-
umes with 0.2 μM concentrations of each primer using the
IQ SYBR GREEN Super mix (Bio-Rad, Hercules, CA). The
principle of the real-time PCR has been described else-
where [65]. Briefly, following activation of the iTaq™ DNA
polymerase for 10 min at 95°C, 40 cycles (15 s at 95°C and
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detection system (Bio-Rad). The positive controls consisted
of the retroviral plasmid containing the gene to be tested.
As negative control, samples consisting of distilled water
were also subjected to the DNA/RNA extraction procedure
and the resulting extracts were amplified. Standard graphs
of the CT values obtained from serial dilutions (10 to 106
copies) of the retroviral plasmids were constructed, and the
CT values from unknown samples were plotted on the
standard curves. Subsequently, copy number of the gene
was calculated. Copy numbers of the plasmids and the
number of human cells that 20 ng genomic DNAs
were extracted from were calculated with the formula as
following: number of copies/cells = (amount * 6.022×1023)/
(length * 1×109 * 650) [http://cels.uri.edu/gsc/cndna.html],
with amount referring to the amount of DNA present in
ngs and length referring to the length of plasmid or amount
of DNA in a single human cell in bp. The length of mutant
tRNALys3-containing retroviral plasmid was 9638 bp and
length of DNA from a single human cell is about 6.6x109
bp [http://users.rcn.com/jkimball.ma.ultranet/BiologyPages/
G/GenomeSizes.html]. Relative expression of Mt13TD ver-
sus wild-type tRNALys3 was calculated through dividing the
copy number of Mt13TD by the copy number of wild-type
tRNALys3.
Statistical analysis
Origin 6.0 professional software (OriginLab Corporation)
was used for two-population t-tests or one-way ANOVA
analysis. P < 0.05 was considered statistically significant.
* indicates 0.01 < P < 0.05; ** indicates 0.001 < P < 0.01;
*** indicates P < 0.001.
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